



# UGOLAB PRODUCTIONS (NIG.) LTD.

MANUFACTURERS OF PHARMACEUTICAL PRODUCTS AND GENERAL MERCHANTS

Head office: 31A Burma Road, Sabon Gari, Kano.

Factory: 157/159, Club Road, Bompai Ind. Layout, Kano.

Tel: +234 (80) 23094219

Website: www.ugolab.com

Email: ugolabpharm@yahoo.com

## SUMMARY OF PRODUCT CHARACTERISTICS MIST MAG

### 1. Name of the medicinal product

MIST MAG

### 2. Qualitative and quantitative composition

Magnesium Carbonate Light	250mg/5ml
Magnesium Trisilicate	250mg/5ml
Sodium bicarbonate	250mg/5ml

For the full list of excipients see section 6.1

### 3. Pharmaceutical form

Oral Mixture

### 4. Clinical particulars

#### 4.1 Therapeutic indications

For relief of the symptoms of indigestion, heartburn and dyspepsia.

#### 4.2 Posology and method of administration

Oral

### RECOMMENDED DOSE

Adults and children over 12 years: two to four 5ml spoonfuls.

Children 5 to 12 years: one to two 5ml spoonfuls.

Directions for use: shake the bottle.



# UGOLAB PRODUCTIONS (NIG.) LTD.

MANUFACTURERS OF PHARMACEUTICAL PRODUCTS AND GENERAL MERCHANTS

Head office: 31A Burma Road, Sabon Gari, Kano.

Factory: 157/159, Club Road, Bompai Ind. Layout, Kano.

Tel: +234 (80) 23094219

Website: [www.ugolab.com](http://www.ugolab.com)

Email: [ugolabpharm@yahoo.com](mailto:ugolabpharm@yahoo.com)

## SUMMARY OF PRODUCT CHARACTERISTICS MIST MAG

Take in a little water.

### DOSAGE SCHEDULE

To be taken three times a day after meals or as required.

### **4.3 Contraindications**

Contraindicated in severe renal failure, hypophosphataemia and in patients who must control sodium intake e.g. congestive heart failure, hypertension, cirrhosis of the liver.

Should not be administered to patients with metabolic or respiratory alkalosis, hypocalcaemia or hypochlorhydria.

Hypersensitivity to any of the ingredients.

### **4.4 Special warnings and precautions for use**

The product should be used with caution in patients with fluid retention. In view of the sodium hydrogen carbonate content, the product should also be administered extremely cautiously to patients with renal impairment, to patients receiving corticosteroids or patients with respiratory acidosis, eclampsia, or aldosteronism.

If renal function is impaired hypermagnesaemia may result giving the symptoms described under (4.9) overdose.

The following warnings and precautions appear on the labels:

Keep out of the reach and sight of children.

Do not give to children under 5 years old unless your doctor tells you to.

Once opened use within 28 days.

If symptoms persist consult your doctor.

### **4.5 Interaction with other medicinal products and other forms of interaction**



# UGOLAB PRODUCTIONS (NIG.) LTD.

MANUFACTURERS OF PHARMACEUTICAL PRODUCTS AND GENERAL MERCHANTS

Head office: 31A Burma Road, Sabon Gari, Kano.

Factory: 157/159, Club Road, Bompai Ind. Layout, Kano.

Tel: +234 (80) 23094219

Website: [www.ugolab.com](http://www.ugolab.com)

Email: [ugolabpharm@yahoo.com](mailto:ugolabpharm@yahoo.com)

## SUMMARY OF PRODUCT CHARACTERISTICS MIST MAG

Antacids may interact with a number of other drugs by altering their absorption and, sometimes, their elimination, thereby reducing their effectiveness. Antacids may also damage enteric coatings designed to prevent dissolution in the stomach. In order to minimize the risk of interactions, this product should not be taken within two to four hours of other medications (allow at least 4 hours before or 2 hours after erlotinib).

Examples of other medications which may be affected include, but are not limited to ACE inhibitors, salicylates e.g. aspirin, atazanavir, azithromycin, barbiturates, bile acids, bisphosphonates, cephalosporin antibiotics, fluoroquinolone antibiotics, chloroquine and hydroxychloroquine, deflazacort, digoxin, dipyridamole, eltrombopag, erlotinib, fexofenadine, gabapentin, iron preparations, isoniazid, itraconazole, ketoconazole, lansoprazole, levothyroxine, lithium, methenamine, mycophenolate, nitrofurantoin, penicillamine, phenothiazines, phenytoin, proguanil, rifampicin, rosuvastatin, sulpiride, tetracyclines, tipranavir, ulipristal (avoid use with antacids).

There is a risk of metabolic alkalosis when oral magnesium salts are given with polystyrene sulphonate resins.

### 4.6 Fertility, pregnancy and lactation

Animal studies are insufficient with respect to effects on pregnancy, embryonal/fetal development, parturition and postnatal development (see section 5.3). The potential risk for humans is unknown. As there is no specific data for this product, it is recommended that Magnesium Trisilicate Mixture only be used in pregnancy on the advice of a doctor. Caution should be exercised when prescribing to pregnant women as this product contains sodium (see Section 4.4).



# UGOLAB PRODUCTIONS (NIG.) LTD.

*MANUFACTURERS OF PHARMACEUTICAL PRODUCTS AND GENERAL MERCHANTS*

Head office: 31A Burma Road, Sabon Gari, Kano.

Factory: 157/159, Club Road, Bompai Ind. Layout, Kano.

Tel: +234 (80) 23094219

Website: [www.ugolab.com](http://www.ugolab.com)

Email: [ugolabpharm@yahoo.com](mailto:ugolabpharm@yahoo.com)

## SUMMARY OF PRODUCT CHARACTERISTICS MIST MAG

### 4.7 Effects on ability to drive and use machines

None.

### 4.8 Undesirable effects

Magnesium salts may cause diarrhea in some patients. Magnesium carbonate and sodium bicarbonate may cause stomach cramps and flatulence as a result of excess carbon dioxide production.

Long-term, excessive use has been associated with the development of silica-based renal calculi.

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

### 4.9 Overdose

Overdose, or excessive or prolonged intake of magnesium containing antacids may give rise to hypermagnesaemia, and excessive administration of sodium hydrogen carbonate may lead to hypokalaemia and metabolic alkalosis, especially in patients with renal insufficiency.

Symptoms of hypermagnesaemia include nausea, vomiting, flushing of the skin, thirst, drowsiness, hypotension, confusion, muscle weakness, CNS and respiratory depression, hyporeflexia, peripheral vasodilatation, bradycardia, cardiac arrhythmias, coma and cardiac arrest.

Symptoms of hypokalemia and metabolic alkalosis include mood changes, tiredness, shortness of breath, muscle weakness and irregular heartbeat. Muscle hypertonicity, twitching and tetany may develop, especially in hypocalcaemia patients. Excessive doses of sodium salts may lead to sodium overloading and hyper osmolality.



# UGOLAB PRODUCTIONS (NIG.) LTD.

*MANUFACTURERS OF PHARMACEUTICAL PRODUCTS AND GENERAL MERCHANTS*

Head office: 31A Burma Road, Sabon Gari, Kano.

Factory: 157/159, Club Road, Bompai Ind. Layout, Kano.

Tel: +234 (80) 23094219

Website: [www.ugolab.com](http://www.ugolab.com)

Email: [ugolabpharm@yahoo.com](mailto:ugolabpharm@yahoo.com)

## SUMMARY OF PRODUCT CHARACTERISTICS MIST MAG

Treatment of mild hypermagnesaemia is usually limited to restricting magnesium intake. In severe hypermagnesaemia, ventilatory and circulatory support may be required. Treatment should consist of the intravenous administration of calcium gluconate injection 10% at a dose of 10 – 20ml, to counteract respiratory depression or heart block. If renal function is normal, adequate fluids should be given to assist magnesium removal from the body. Haemodialysis may be necessary in patients with renal impairment or for whom other methods prove ineffective. Metabolic alkalosis and hyponatremia can be treated by appropriate correction of fluid and electrolyte balance. Replacement of calcium, chloride, and potassium ions may be of particular importance.

### 5. Pharmacological properties

#### 5.1 Pharmacodynamic properties

Magnesium trisilicate mixture is an antacid with slow neutralising action and mild laxative action.

#### 5.2 Pharmacokinetic properties

Magnesium chloride and hydrated silica gel are formed during the neutralization. About 5% of magnesium is absorbed and traces of liberated silica may be absorbed and excreted in the urine.

Any sodium hydrogen carbonate not neutralised in the stomach is absorbed and excreted as bicarbonate and sodium ions in the urine in the absence of a plasma deficit.

#### 5.3 Preclinical safety data

None Known.

### 6. Pharmaceutical particulars



# UGOLAB PRODUCTIONS (NIG.) LTD.

MANUFACTURERS OF PHARMACEUTICAL PRODUCTS AND GENERAL MERCHANTS

Head office: 31A Burma Road, Sabon Gari, Kano.

Factory: 157/159, Club Road, Bompai Ind. Layout, Kano.

Tel: +234 (80) 23094219

Website: [www.ugolab.com](http://www.ugolab.com)

Email: [ugolabpharm@yahoo.com](mailto:ugolabpharm@yahoo.com)

## SUMMARY OF PRODUCT CHARACTERISTICS MIST MAG

### 6.1 List of excipients

NA SACCHARINE  
METHYL PARABEN  
NATROSOL  
PEPPERMINT OIL  
CHLOROFORM

### 6.2 Incompatibilities

None.

### 6.3 Shelf life

36 months

### 6.4 Special precautions for storage

Store below 25°C.

### 6.5 Nature and contents of container

Bottle:	Amber PET , Plain PET
Closures:	28mm ROPP, tamper evident, child resistant.
Pack Sizes:	200ml. 2L

### 6.6 Special precautions for disposal and other handling

None.

## 7. Marketing authorisation holder



# UGOLAB PRODUCTIONS (NIG.) LTD.

*MANUFACTURERS OF PHARMACEUTICAL PRODUCTS AND GENERAL MERCHANTS*

**Head office:** 31A Burma Road, Sabon Gari, Kano.

**Factory:** 157/159, Club Road, Bompai Ind. Layout, Kano.

**Tel:** +234 (80) 23094219

**Website:** www.ugolab.com

**Email:** ugolabpharm@yahoo.com

---

## SUMMARY OF PRODUCT CHARACTERISTICS MIST MAG

UGOLAB PRODUCTIONS NIG. LTD  
157/159 CLUB ROAD, BOMPAI INDU LAYOUT, KANO.  
KANO STATE.  
NIGERIA.

### **8. Marketing authorisation number(s)**

04-1325

### **9. Date of first authorisation/renewal of the authorisation**

26<sup>th</sup> March 2015

### **10. Date of revision of the text**

Not Applicable

### **Company Contact Details**

UGOLAB PRODUCTIONS NIG. LTD

#### **Address**

31A Burma road, Sabon gari, Kano.  
Kano State.  
Nigeria

#### **Telephone**

+234 (80) 23094219  
ugolabpharm@yahoo.com